DrugPatentWatch Database Preview

Details for Patent: 8,618,174

« Back to Dashboard

Which drugs does patent 8,618,174 protect, and when does it expire?

Patent 8,618,174 protects AMTURNIDE and is included in one NDA.

This patent has seventy-six patent family members in thirty-one countries.

Summary for Patent: 8,618,174

Title:	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
Abstract:	The invention relates to a combination comprising the renin inhibitor of formula (I) ##STR00001## or a pharmaceutically acceptable salt thereof.
Inventor(s):	Hewitt; William (Pottstown, PA), Vasella; Daniel L (Basel, CH), Webb; Randy L (Flemington, NJ)
Assignee:	Novartis AG (Basel, CH)
Application Number:	13/235,787
Patent Claim Types: see list of patent claims	Composition; Compound; Use;

Drugs Protected by US Patent 8,618,174

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Novartis	AMTURNIDE	aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide	TABLET;ORAL	200045-001	Dec 21, 2010		DISCN	No	No			Y
Novartis	AMTURNIDE	aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide	TABLET;ORAL	200045-002	Dec 21, 2010		DISCN	No	No			Y
Novartis	AMTURNIDE	aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide	TABLET;ORAL	200045-003	Dec 21, 2010		DISCN	No	No			Y
Novartis	AMTURNIDE	aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide	TABLET;ORAL	200045-004	Dec 21, 2010		DISCN	No	No			Y

Foreign Priority and PCT Information for Patent: 8,618,174

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0028151.9	Nov 17, 2000

Non-Orange Book US Patents Family Members for Patent 8,618,174

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,168,616	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
9,023,894	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
9,023,893	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases

International Family Members for US Patent 8,618,174

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Poland	227576
Poland	361404
New Zealand	568764
New Zealand	550898